U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, ...

California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is ...

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...